Theriva Biologics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Theriva Biologics, Inc. (TOVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 475.00 thousand shares for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2013-11-14
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2013-09-30 was 55.56K shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2013-06-30 was 361.11K shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2013-03-31 was 58.33K shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2012-12-31 was 450.83K shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2011 was 93.75K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2013-09-30 | 55.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | 416.67K shares derived: sum of 2 quarters · filed 2013-11-14 | 475.00K shares 10-Q · filed 2013-11-14 | 925.83K shares derived: sum of 4 quarters · filed 2013-11-14 | |
| 2013-06-30 | 361.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | 419.44K shares 10-Q · filed 2013-08-14 | 870.27K shares derived: sum of 3 quarters · filed 2013-11-14 | 870.27K shares derived: sum of 4 quarters · filed 2013-11-14 | |
| 2013-03-31 | 58.33K shares 10-Q · filed 2013-05-15 | 509.16K shares derived: sum of 2 quarters · filed 2013-11-14 | 509.16K shares derived: sum of 3 quarters · filed 2013-11-14 | ||
| 2012-12-31 | 450.83K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2013-11-14 | 450.83K shares derived: sum of 2 quarters · filed 2013-11-14 | 225.41K shares 10-Q · filed 2013-11-14 | ||
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-14 | -225.41K shares 10-Q · filed 2012-11-14 | |||
| 2012-06-30 | -225.41K shares 10-Q/A · filed 2012-09-11 | ||||
| 2011-12-31 | 93.75K shares 10-K · filed 2013-04-16 | -93.75K shares 10-Q/A · filed 2012-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |